Pfizer-Bio NTech vaccine

URI: https://gptkb.org/entity/Pfizer-Bio_NTech_vaccine
GPTKB entity
Statements (58)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:accessories gptkb:various_countries
gptkb:COVAX
gptkbp:approves gptkb:FDA
gptkb:EMA
December 2020
gptkbp:average_temperature -70 degrees Celsius
gptkbp:brand gptkb:Comirnaty
gptkbp:clinical_trial gptkb:Germany
gptkb:United_States
Phase 3
44,000
gptkbp:community_health reduced hospitalizations
reduced deaths
gptkbp:developed_by gptkb:Pfizer
gptkb:Bio_NTech
gptkbp:dosage_form recommended after initial series
two doses
gptkbp:effectiveness_against_variants reduced against Delta variant
reduced against Omicron variant
https://www.w3.org/2000/01/rdf-schema#label Pfizer-Bio NTech vaccine
gptkbp:is_effective_against 95% in clinical trials
gptkbp:is_vulnerable_to gptkb:January_6,_2021
January 3, 2022
global
December 11, 2020
October 12, 2022
October 29, 2021
May 10, 2021
August 31, 2022
August 23, 2021
preventive
lipid nanoparticle
December 23, 2022
December 9, 2021
September 12, 2022
March 29, 2022
November 17, 2022
May 17, 2022
gptkbp:manufacturer gptkb:Bio_NTech_SE
gptkb:Pfizer_Inc.
gptkbp:route_of_administration intramuscular injection
gptkbp:safety_measures VSD
VAERS
gptkbp:side_effect fatigue
headache
muscle pain
fever
joint pain
chills
gptkbp:targets gptkb:COVID-19
gptkbp:type gptkb:vaccine
gptkbp:vaccine_efficacy_duration 6 months
longer with booster
gptkbp:whoemergency_use_listing yes
gptkbp:bfsParent gptkb:B.1.1.7_variant
gptkb:NHS_COVID-19_vaccination_program
gptkbp:bfsLayer 7